4,5-Diaryl-1H-pyrrole-2-carboxylates as combretastatin A-4/lamellarin T hybrids: Synthesis and evaluation as anti-mitotic and cytotoxic agents

Bioorganic and Medicinal Chemistry

Volumn 14, Issue 13, 2006, Pages 4627-4638

  Banwell, Martin G ^a   Hamel, Ernest ^b   Hockless, David C R ^a   Verdier Pinard, Pascal ^b   Willis, Anthony C ^a   Wong, David J ^a  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^b Developmental Therapeutics Program   (United States)

Author keywords

Anti mitotic; cis Stilbene; Combretastatin A 4; Cytotoxic; Lamellarin T

Indexed keywords

(5 IODO 2 METHOXYPHENOXY)(TERT BUTYL)DIMETHYLSILANE; 3 [[(TERT BUTYL)DIMETHYLSILYL]OXY] 4 METHOXYPHENYLBORONIC ACID; 3,4,5 TRIMETHOXYPHENYLBORONIC ACID; 4,5 1H PYRROLE 2 CARBOXYLATE DERIVATIVE; 5 IODO 1,2,3 TRIMETHOXYBENZENE; ALKALOID DERIVATIVE; ANTIMITOTIC AGENT; CARBOXYLIC ACID DERIVATIVE; COMBRETASTATIN; HALOGEN; LAMELLARIN; LITHIUM; METHYL 1 (4 METHOXYBENZYL) 1H PYRROLE 2 CARBOXYLATE; METHYL 1 (4 METHOXYBENZYL) 4 (3 HYDROXY 4 METHOXYPHENYL) 5 (3,4,5 TRIMETHOXYPHENYL) 1H PYRROLE 2 CARBOXYLATE; METHYL 1 (4 METHOXYBENZYL) 4 (BENZO[D][1,3] DIOXOL 6 YL) 5 (3 HYDROXY 4 METHOXYPHENYL) 1H PYRROLE 2 CARBOXYLATE; METHYL 1 (4 METHOXYBENZYL) 4 BROMO 5 (3,4,5 TRIMETHOXYPHENYL) 1H PYRROLE 2 CARBOXYLATE; METHYL 1 (4 METHOXYBENZYL) 5 (3 HYDROXY 4 METHOXYPHENYL) 4 (3,4,5 TRIMETHOXYPHENYL) 1H PYRROLE 2 CARBOXYLATE; METHYL 1 BENZYL 1H PYRROLE 2 CARBOXYLATE; METHYL 1 BENZYL 4 (4 METHOXYPHENYL) 5 PHENYL 1H PYRROLE 2 CARBOXYLATE; METHYL 1H PYRROLE 2 CARBOXYLATE; METHYL 4 (3 HYDROXY 4 METHOXYPHENYL) 5 (3,4,5 TRIMETHOXYPHENYL) 1H PYRROLE 2 CARBOXYLATE; METHYL 4 (BENZO[D][1,3] DIOXOL 6 YL) 5 (3 HYDROXY 4 METHOXYPHENYL) 1H PYRROLE 2 CARBOXYLATE; METHYL 4 BROMO 1 BENZYL 5 PHENYL 1H PYRROLE 2 CARBOXYLATE; METHYL 4 BROMO 5 [[(TERT BUTYL)DIMETHYLSILYLOXY 4 METHOXYPHENYL] 1 (4 METHOXYBENZYL)] 1H PYRROLE 2 CARBOXYLATE; METHYL 4,5 DIBROMO (4 METHOXYBENZYL) 1H PYRROLE 2 CARBOXYLATE; METHYL 4,5 DIBROMO 1 BENZYL 1H PYRROLE 2 CARBOXYLATE; METHYL 4,5 DIBROMO 1H PYRROLE 2 CARBOXYLATE; METHYL 5 (3 HYDROXY 4 METHOXYPHENYL) 4 (3,4,5 TRIMETHOXYPHENYL) 1H PYRROLE 2 CARBOXYLATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CROSS COUPLING REACTION; CYTOTOXICITY; DRUG INHIBITION; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYBRID; IC 50; NONHUMAN; SUZUKI REACTION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMITOTIC AGENTS; CATTLE; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; PROLINE; STILBENES; TUBULIN;

EID: 33646750713     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2006.02.018     Document Type: Article

References (39)

1. Hsieh H.P., Liou J.P., and Mahindroo N. Curr. Pharm. Des. 11 (2005) 1655
2. Cirla A., and Mann J. Nat. Prod. Rep. 20 (2003) 558 and references cited therein
3. Griggs J., Metclafe J.C., and Hesketh R. Lancet Oncol. 2 (2001) 82
4. See, for example. Pettit G.R., Rhodes M.R., Herald D.L., Hamel E., Schmidt J.M., and Pettit R.K. J. Med. Chem. 48 (2005) 4087
5. Pettit G.R., Anderson C.R., Gapud E.J., Jung M.K., Knight J.C., Hamel E., and Pettit R.K. J. Nat. Prod. 68 (2005) 1191
6. Simoni D., Grisolia G., Giannini G., Roberti M., Rondanin R., Piccagli L., Baruchello R., Rossi M., Romagnoli R., Invidiata F.P., Grimaudo S., Jung M.K., Hamel E., Gebbia N., Crosta L., Abbadessa V., Di Cristina A., Dusonchet L., Meli M., and Tolomeo M. J. Med. Chem. 48 (2005) 723 and references cited therein
7. Hadimani M.B., Hua J., Jonklass M.D., Kessler R.J., Sheng Y., Olivares A., Tanpure R.P., Weiser A., Zhang J., Edvardsen K., Kane R.R., and Pinney K.G. Bioorg. Med. Chem. Lett. 13 (2003) 1505
8. For a very recent and useful review of this area see: (a) Current Medicinal Chemistry-Anti-Cancer Agents; Bailly, C., Ed.; Bentham Science Publishers Ltd: Sharjah, United Arab Emirates, 2004; Vol. 4, p 363.
9. See, also. Marfil M., Albericio F., and Álvarez M. Tetrahedron 60 (2004) 8659 for an up-to-date commentary on the biological profiles of this group of natural products
10. Banwell M.G., Herbert K.A., Buckleton J.R., Clark G.R., Rickard C.E.F., Lin C.M., and Hamel E. J. Org. Chem. 53 (1988) 4945
11. Banwell M.G., Cameron J.M., Collis M.P., Crisp G.T., Gable R.W., Hamel E., Lambert J.N., Mackay M.F., Reum M.E., and Scoble J.A. Aust. J. Chem. 44 (1991) 705
12. Banwell M.G., Cameron J.M., Corbett M., Dupuche J.R., Hamel E., Lambert J.N., Lin C.M., and Mackay M.F. Aust. J. Chem. 45 (1992) 1967
13. Banwell M.G., Fam M.-A., Gable R.W., and Hamel E. J. Chem. Soc., Chem. Commun. (1994) 2647
14. Banwell M.G., Hamel E., Ireland N.K., and Mackay M.F. Heterocycles 39 (1994) 205
15. Banwell M.G., Flynn B.L., Willis A.C., and Hamel E. Aust. J. Chem. 52 (1999) 767
16. Banwell M.G., Edwards A.J., Jolliffe K.A., Smith J.A., Hamel E., and Verdier-Pinard P. Org. Biomol. Chem. 1 (2003) 296
17. Banwell M.G., Bezos A., Burns C., Kruszelnicki I., Parish C.R., Su S., and Sydnes M.O. Bioorg. Med. Chem. Lett. 16 (2006) 181
18. We have previously reported on the preparation of the isomeric methyl 3,4-diaryl-1H-pyrrole-2-carboxylates as lamellarin/colchicine hybrids and, therefore, potential anti-mitotic agents:. Banwell M.G., Flynn B.L., Hamel E., and Hockless D.C.R. Chem. Commun. (1997) 207
19. Certain 4,5-diarylated pyrroles incorporating electron-withdrawing substituents have been investigated as anti-inflammatory agents or as drugs for the treatment of complications arising from diabetes:. Wilkerson W.W., Galbraith W., Gans-Brangs K., Grubb M., Hewes W.E., Jaffee B., Kenney J.P., Kerr J., and Wong N. J. Med. Chem. 37 (1994) 988 and references cited therein
20. Wilkerson W.W., Copeland R.A., Covington M., and Trzaskos J.M. J. Med. Chem. 38 (1995) 3895
21. de Laszlo S.E., Hacker C., Li B., Kim D., MacCoss M., Mantlo N., Pivnichny J.V., Colwell L., Koch G.E., Cascieri M.A., and Hagmann W.K. Bioorg. Med. Chem. Lett. 9 (1999) 641
22. Agrawal V.K., Joseph S., Khadikar P.V., and Karmarkar S. Acta Pharm. 50 (2000) 329
23. 4a
24. For an up-to-date 'mini-review' on palladium-catalysed cross-coupling reactions involving pyrroles, see: Banwell, M. G.; Goodwin, T. E.; Ng, S.; Smith, J. A.; Wong, D. J. Eur. J. Org. Chem. accepted for publication.
25. Firl J., and Kresze G. Chem. Ber. 99 (1966) 3695
26. Anderson H.J., and Lee S.-F. Can. J. Chem. 43 (1965) 409
27. Anderson H.J., and Griffiths S.J. Can. J. Chem. 45 (1967) 2227
28. Bacon R.G.R., and Wright J.R. J. Chem. Soc. (C) (1969) 1978
29. Jones M.I., Froussios C., and Evans D.A. J. Chem. Soc., Chem. Commun. (1976) 472
30. Feldman K.S. J. Org. Chem. 62 (1997) 4983
31. Berryman, K. A.; Bunker, A. M.; Doherty, A. M.; Edmunds, J. J. PCT Int. Appl. 1996, WO9626195.
32. Banwell, M. G.; Flynn, B. L.; Hamel, E. Unpublished observations.
33. Still W.C., Kahn M., and Mitra A. J. Org. Chem. 43 (1978) 2923
34. Armarego W.L.F., and Perrin D.D. Purification of Laboratory Chemicals. fourth ed. (1996), Butterworth-Heinemann, Oxford, UK
35. Altomare A., Cascarano M., Giacovazzo C., and Guagliardi A. J. Appl. Crystallogr. 26 (1993) 343
36. teXsan: Single Crystal Structure Analysis Software. Version 1.8. Molecular Structure Corporation: The Woodlands, TX 77381, USA, 1997.
37. Hamel E., and Lin C.M. Biochemistry 23 (1984) 4173
38. Hamel E. Cell Biochem. Biophys. 38 (2003) 1
39. Verdier-Pinard P., Lai J.-Y., Yoo H.-D., Yu J., Marquez B., Nagle D.G., Nambu M., White J.D., Falck J.R., Gerwick W.H., Day B.W., and Hamel E. Mol. Pharmacol. 53 (1998) 62